CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Chicago, Illinois, United States and 250 other locations
and pembrolizumab) given together for the treatment of colorectal cancer that:* is metastatic (spread to other parts of the body);* has the ...
Phase 2
Chicago, Illinois, United States and 111 other locations
dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, an...
Phase 1
Chicago, Illinois, United States and 32 other locations
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
Chicago, Illinois, United States and 83 other locations
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...
Phase 2, Phase 3
Chicago, Illinois, United States and 878 other locations
dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors...
Phase 1
Chicago, Illinois, United States and 3 other locations
tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors...
Phase 1
Chicago, Illinois, United States and 11 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
Chicago, Illinois, United States and 18 other locations
plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treat...
Phase 3
Chicago, Illinois, United States and 152 other locations
evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors...
Phase 1, Phase 2
Chicago, Illinois, United States and 219 other locations
Clinical trials
Research sites
Resources
Legal